FIG 6 .

SAMHD1 is required for TKI-induced restriction. (A) Summary flow cytometric analysis of HIV-1 infection in four separate donors treated with various TKIs. The TKIs were dasatinib (DAS), crenolanib (CRE), bosutinib (BOS), palbociclib (PAL), and ponatinib (PON). Values indicate the percent GFP-positive cells within the viable population of cells infected with HIV-1ΔEnv-GFP/VSVG. The viability of TKI-treated cells is between 90 and 100% that of untreated cells (No Tx). (B) Western blot analysis of lysates of MDM from two representative donors treated with the indicated concentration of dasatinib. (C) Correlation between relative pSAMHD1-T592 and infectivity for macrophages from six donors treated with 0 nM, 50 nM, and 100 nM dasatinib. (D) MDM treated with 500 nM dasatinib and treated with the Vpx VLP indicated. Numbers represent the percentage of live cells within the GFP-positive gate as established with mock-infected MDM. Linear regression analysis was performed to study the relationship between infectivity and pSAMHD1 levels during dasatinib treatment.